Results 91 to 100 of about 27,256 (249)

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat) [PDF]

, 2017
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of obese type 2 diabetes.
Fernandes, Rosa, Ferreira, Liliana, Garrido, Patrícia, Mega, Cristina, Melo, Andreia, Nunes, Sara, Parada, Belmiro, Pinto, Filipa, Pinto, Rui, Reis, Flávio, Santos, Paulo, Sereno, José, Teixeira, Frederico, Teixeira-de-Lemos, Edite, Vala, Helena, Velada, Isabel   +15 more
core  

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes : systematic review and economic evaluation [PDF]

, 2017
Background Most people with type 2 diabetes are overweight, so initial treatment is aimed at reducing weight and increasing physical activity. Even modest weight loss can improve control of blood glucose.
Clar, Christine, Clegg, Andrew, Colquitt, Jill, Court, Rachel A., Cummins, Ewen, Holt, Tim, Johnston, Rhona, McGrane, David, O'Hare, J. Paul, Royle, Pamela, Shantikumar, Saran, Tan, Bee K., Uthman, Olalekan A., Waugh, Norman   +13 more
core   +3 more sources

Estimating the risk of cardiovascular outcomes and all‐cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1068-1075, February 2026.
Abstract Aims To evaluate United Kingdom Prospective Diabetes Study Outcomes Model version 2 (UKPDS‐OM2) cardiovascular risk estimates for people with type 2 diabetes using TECOS and EXSCEL data. Materials and methods We compared model‐simulated and TECOS and EXSCEL observed event rates for the composite outcome of cardiovascular death, myocardial ...
Ruth L. Coleman, Amanda I. Adler, Philip M. Clarke, Darren K. McGuire, Rury R. Holman   +4 more
wiley   +1 more source

Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold [PDF]

, 2015
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed.
Biftu T., Borne R. F., Chutian S., Drucker D. J., Drucker D. J., Hawkins P. C. D., Herman G. A., Juillerat-Jeanneret L., Kim D., Nauck M., Occhiato E. G., Orsakov C., Schwehm C., Thomsen I., Thornberry N. A.   +14 more
core   +3 more sources

Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Sören Dräger, Claudia Kauderer, Svenja Meyhöfer, Leonie Dräger, Jens U. Marquardt, Ralf J. Ludwig, Stephan Arndt, Katharina Boch, Katja Bieber   +8 more
wiley   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundDiminished growth hormone (GH) is associated with impaired endothelial function and fibrinolysis. GH‐releasing hormone is the primary stimulus for GH secretion and a substrate of dipeptidyl peptidase‐4.
Jessica R. Wilson, Nancy J. Brown, Hui Nian, Chang Yu, Martin Bidlingmaier, Jessica K. Devin   +5 more
doaj   +1 more source

DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid [PDF]

, 2016
Additional file 3: Figure S2. Liver and epididymal fat weights in db/+ mice and db/db mice. The experiments were performed in db/+ or db/db mice fed an SL diet, SO diet, SL containing DPP-4 inhibitor (0.4% des-fluoro-sitagliptin) diet, or SO containing ...
Eiko Yoshida, Hajime Sasaki, Jun Shirakawa, Kazuki Tajima, Mayu Kyohara, Megumi Koganei, Mitsuyo Kaji, Shunsuke Yamazaki, Tomoko Okuyama, Yasuo Terauchi, Yu Togashi   +10 more
core   +5 more sources

Efficacy and safety of bi‐weekly cofrogliptin treatment replacing daily dipeptidyl peptidase‐4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open‐label, randomized controlled phase 2 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1191-1200, February 2026.
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Congqing Pan, Hongwei Jiang, Yi Feng, Suijun Wang, Jin Zhang, Zhongjing Wang, Yusen Zhou, Fangqiong Li, Zhanhui Zhang, Yaming Li, Liming Chen   +10 more
wiley   +1 more source

DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF SITAGLIPTIN AND METFORMIN IN BULK AND COMBINED PHARMACEUTICAL FORMULATION

, 2022
K. BHAVYA SRI, G. SRI VANI SHAILAJA, Narmada Vallakeerthi, V. KIRAN KUMAR, M. SUMAKANTH   +4 more
openalex   +2 more sources